liminatuspharma.com - LIMN Income before deduction of interest, taxes and amortization
Liminatus Pharma is investing in R&D for gastrointestinal tumor vaccines while the market awaits the start of clinical trials. The company's absolute operating profit in cash demonstrates real cash flow, where the value of 0.00 reflects this status. Recruiting leading oncologists to develop CAR-T therapy provides the scientific foundation for the issuer's future success.
Liminatus Pharma LLC - analytical breakdowns and key metrics (LIMN)
- market value and analyst target forecast:
- issuer market value details:
- book capitalization information:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
LIMN - Net Income|Future Net Profit Liminatus Pharma|LIMN - P/E Multiple|Future Price to Earnings Multiple liminatuspharma.com|LIMN - PEG Multiple|Company Value to EBITDA Liminatus Pharma|LIMN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Liminatus Pharma|LIMN - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth liminatuspharma.com|LIMN - Earnings per share growth in current year|Net earnings per share change forecast for next year Liminatus Pharma
Analysis of all company metrics:Liminatus - LIMN
Diversifying its cell therapy portfolio for solid tumors allows Liminatus Pharma (LIMN) to scale patient reach while minimizing the specific risks associated with oncological development. This metric measures the actual cash flow from core operations before depreciation and taxes, helping investors assess the fundamental stability of the business by tracking absolute EBITDA deviations to avoid overpaying for the asset.
Competitors of Liminatus Pharma (LIMN)
NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Profit before payment of interest, taxes and amortization Immatics N.V. (IMTX)|Operating profit before deduction of amortization xencor.com XNCR|Compass Therapeutics, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Group Inc REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (Innate Pharma S.A) - Operating profit before amortization|pyxisoncology.com (PYXS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Compugen (CGEN)|Operating profit before deduction of amortization IOBT|STRO - Operating profit before depreciation charges|Operating profit before deduction of amortization INKT (MiNK)|Company profit before taxes, interest and amortization HOWL|Operating profit EBITDA IMMX (Immix Biopharma)|Income before deduction of interest, taxes and amortization ALXO|Cue Biopharma, Inc. - Operating profit EBITDA|Profit before interest, taxes and amortization PDS Biotechnology|sonnetbio.com (SONN) - Profit before payment of interest, taxes and amortization|MAIA Bio - Income before deduction of interest, taxes and amortization|LVTX (LAVA Therapeutics NV) - Operating profit EBITDA|Operating profit EBITDA nextcure.com|Profit before payment of interest, taxes and amortization Leap Therapeutics, Inc. (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|GRTS - Profit before payment of interest, taxes and amortization|KA: Profit before payment of interest, taxes and amortization|NEXI: Operating profit EBITDA|TSBX - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Vaccinex, Inc|Operating profit before deduction of amortization Harpoon Therapeutics Corp (HARP)
